The US has already invested billions in potential coronavirus vaccines. Here’s where the deals stand

• So far, the federal government has made deals with a handful of pharmaceutical giants that have raised roughly $ 10.79 billion as part of Operation Warp Speed.
• The operation aims to deliver at least 300 million doses of a coronavirus vaccine by January 2021.
• Moderna, Johnson & Johnson, Pfizer and BioNTech, Sanofi and GlaxoSmithKline, Novavax and AstraZeneca have all received financing from the operation for their fax machines.

© Provided by CNBC
A small bottle marked with a

The US has pledged billions to develop a vaccine against the coronavirus that has infected more than 5.1 million people across the country, included in a minimum of 800 million doses as soon as the immunizations become available later this year or early next year delete.

Load error

To date, deals with a handful of pharmaceutical giants have grossed roughly $ 10.79 billion as part of Operation Warp Speed, a program led by various departments within the federal government to develop, manufacture, and distribute faxes and treatments. accelerate to fight the coronavirus.

The operation aims to deliver at least 300 million doses of a coronavirus vaccine by January 2021.. In most of the agreements, the Department of Health and Human Services says that the vaccines will be given to the American people free of charge as part of a vaccination campaign. Once the faxes are approved, the campaign aims to deliver them quickly to as many people as possible. The federal government has said it will cover the cost of delivery, but health care providers may pay to administer the vaccine.

Dr Purvi Parikh: Vaccine for Covid-19 may be available in summer 2021

Click to expand

FOLLOWING

“It is likely that by the beginning of next year we will have tens of millions of doses available,” said Drs. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, reporters on a conference call alongside National Institutes of Health Director Dr. Francis Collins on July 27th.

“I think if we come in 2021, several months from now, you would have faxes that would be widely available,” Fauci said.

Experts say some of the top vaccine candidates are already being produced “at risk,” meaning the doses have been made and prepared for deployment before official approval from the U.S. Food and Drug Administration.

“We are investing in the development and manufacturing of the top six vaccine candidates to ensure prompt delivery. The Army is ready to go, they are ready to deliver a vaccine to Americans once one is fully approved by the FDA and we ‘ re very close to that approval, ”President Donald Trump said during a news conference at the White House.

Timeline for a fax is not so important for markets: investor

Click to expand

FOLLOWING

The US is only required to pay the next tranche of funds if the faxes are removed by the Food and Drug Administration.

Here’s where the deals are so far:

Modern

• Trump said Tuesday that the U.S. government is reaching a deal with Massachusetts-based Moderna for 100 million doses of its leading vaccine candidate mRNA-1273.
• The deal gives the federal government the option to purchase up to 400 million additional doses, according to a separate announcement from Moderna. The company said the deal is worth up to $ 1.53 billion.
• The US has already invested $ 955 million in Moderna’s fax development, bringing its total investment to $ 2.48 billion, the company said.
• The Moderna vaccine candidate is in late-stage human studies. The company said earlier that it could already expect results by October.

Johnson and Johnson

• HHS announced on August 5 that it had entered into a deal with Janssen, J & J’s pharmaceutical subsidiary, worth approximately $ 1 billion for 100 million doses of its vaccine.
• The deal gives the federal government the option to order an additional 200 million doses, according to the announcement.
• The US allocated $ 456 million to J & J earlier this year to develop its fax machine.
• J & J’s experimental vaccine is currently in early-stage human studies and is expected to begin human trials in September, executives have said earlier.

Sanofi and GlaxoSmithKline

• Sanofi and GSK, which are jointly developing a vaccine, announced on July 31 that HHS would pay up to $ 2.1 billion to develop and deliver 100 million doses of its potential candidate.
• The US will have the option to order an additional 500 million doses, the companies said.
• More than half of the $ 2.1 billion investment will be used to further develop the vaccine, while the remaining funds will be used to make the initial 100 million doses, the companies said.
• Sanofi and GSK have previously predicted that their vaccine will introduce clinical trials in September and late-stage tests by the end of the year.

Pfizer and BioNTech

• Germany-based BioNTech and Pfizer announced July 22 that the US has agreed to buy 100 million doses of its potential coronavirus vaccine for up to $ 1.95 billion.
• The agreement allows the U.S. to receive an additional dose of 500 million faxes, the companies said.
• BioNTech and Pfizer are working together on four vaccine candidates. The most advanced, called BNT162b1, began late stage human trials.
• The companies said they aim to make up to 100 million doses by the end of 2020 and about 1.3 billion doses by the end of 2021.

Novavax

• HHS announced July 7 that it has reached a $ 1.6 billion deal with Maryland-based drugmaker Novavax to help the company with trials and manufacturing.
• The federal government said as part of the deal Novavax will supply the US with 100 million doses of its experimental coronavirus vaccine.
• The Novavax vaccine, named NVX-CoV2373, generated an enhanced immune response at an early stage of clinical trials and was able to begin early October studies.
• The company said it hopes to start delivering 100 million fax files by the beginning of next year.

AstraZeneca

• HHS announced on May 21 that it would pay AstraZeneca up to $ 1.2 billion for its experimental vaccine developed alongside researchers at the University of Oxford.
• The US will receive at least 300 million doses of the vaccine as part of its investment, HHS said.
• In June, the company in the UK said it was working to deliver 2 billion doses of its vaccine, called AZD1222, and could start distributing doses in the autumn.
• On July 20, the company announced promising results from early-stage human subjects and began late-stage human trials in the United Kingdom, Brazil and South Africa.

– CNBC’s Berkeley Lovelace Jr. en Lucy Handley contributed to this report.

Video: Former FDA chief Scott Gottlieb over New Zealand outbreak, back to school worries (CNBC)

Former FDA chief Scott Gottlieb over New Zealand outbreak, back to school

Click to expand

FOLLOWING